Cargando…

Vitamin D Supplementation for the Treatment of Depressive Symptoms in Women with Type 2 Diabetes: A Randomized Clinical Trial

AIM: To determine the efficacy and safety of vitamin D(3) supplementation in reducing depressive symptoms in women with type 2 diabetes (T2D), depression, and low vitamin D. METHODS: In this double-blind randomized active comparator-controlled trial, women with significant depressive symptoms as ass...

Descripción completa

Detalles Bibliográficos
Autores principales: Penckofer, Sue, Ridosh, Monique, Adams, William, Grzesiak, Meghan, Woo, Jennifer, Byrn, Mary, Kouba, Joanne, Sheean, Patricia, Kordish, Colleen, Durazo-Arvizu, Ramon, Wallis, Diane, Emanuele, Mary Ann, Halaris, Angelos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913152/
https://www.ncbi.nlm.nih.gov/pubmed/35280228
http://dx.doi.org/10.1155/2022/4090807
_version_ 1784667360938950656
author Penckofer, Sue
Ridosh, Monique
Adams, William
Grzesiak, Meghan
Woo, Jennifer
Byrn, Mary
Kouba, Joanne
Sheean, Patricia
Kordish, Colleen
Durazo-Arvizu, Ramon
Wallis, Diane
Emanuele, Mary Ann
Halaris, Angelos
author_facet Penckofer, Sue
Ridosh, Monique
Adams, William
Grzesiak, Meghan
Woo, Jennifer
Byrn, Mary
Kouba, Joanne
Sheean, Patricia
Kordish, Colleen
Durazo-Arvizu, Ramon
Wallis, Diane
Emanuele, Mary Ann
Halaris, Angelos
author_sort Penckofer, Sue
collection PubMed
description AIM: To determine the efficacy and safety of vitamin D(3) supplementation in reducing depressive symptoms in women with type 2 diabetes (T2D), depression, and low vitamin D. METHODS: In this double-blind randomized active comparator-controlled trial, women with significant depressive symptoms as assessed by the Center for Epidemiologic Studies Depression (CES-D) scale received weekly oral vitamin D(3) supplementation (50,000 IU) or an active comparator (5,000 IU) for 6 months. Assessments of vitamin D, 25-hydroxyvitamin D [25 (OH) D], and depression were measured at baseline, 3 months, and 6 months. RESULTS: A total of 129 women were randomized, from which 119 completed the study (57 in lower dose and 62 in higher dose). Participants had an average 25 (OH) D and HbA1c of 20.8 ng/mL and 7.8%, respectively, at baseline. They were diverse (48% Black) and had a mean age of 50 and T2D for about 8 years. Upon completion of vitamin D(3) supplementation, serum 25 (OH) D levels increased with 50,000 IU (+34 ng/mL) and 5,000 IU (+10 ng/mL). There was no difference in CES-D scores by treatment dose. Overall, depressive symptoms significantly improved over time with an average CES-D decline of 12.98 points (95% CI: −15.04 to −10.93; p < 0.001). Among women with moderate baseline depressive symptoms, those receiving the lower dose had nominally lower depression scores at follow-up than those in the higher dose cohort. Among women with severe baseline depressive symptoms, the improvement in follow-up depression scores was the same regardless of dose. CONCLUSIONS: There was no difference in the dosing effect of vitamin D(3) supplementation for the treatment of depressive symptoms in women with T2D who present with significant symptoms and low vitamin D. Regardless of the dose, participants' mood improved over time. Further study of vitamin D to target depressive symptoms in comorbid populations is needed.
format Online
Article
Text
id pubmed-8913152
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-89131522022-03-11 Vitamin D Supplementation for the Treatment of Depressive Symptoms in Women with Type 2 Diabetes: A Randomized Clinical Trial Penckofer, Sue Ridosh, Monique Adams, William Grzesiak, Meghan Woo, Jennifer Byrn, Mary Kouba, Joanne Sheean, Patricia Kordish, Colleen Durazo-Arvizu, Ramon Wallis, Diane Emanuele, Mary Ann Halaris, Angelos J Diabetes Res Research Article AIM: To determine the efficacy and safety of vitamin D(3) supplementation in reducing depressive symptoms in women with type 2 diabetes (T2D), depression, and low vitamin D. METHODS: In this double-blind randomized active comparator-controlled trial, women with significant depressive symptoms as assessed by the Center for Epidemiologic Studies Depression (CES-D) scale received weekly oral vitamin D(3) supplementation (50,000 IU) or an active comparator (5,000 IU) for 6 months. Assessments of vitamin D, 25-hydroxyvitamin D [25 (OH) D], and depression were measured at baseline, 3 months, and 6 months. RESULTS: A total of 129 women were randomized, from which 119 completed the study (57 in lower dose and 62 in higher dose). Participants had an average 25 (OH) D and HbA1c of 20.8 ng/mL and 7.8%, respectively, at baseline. They were diverse (48% Black) and had a mean age of 50 and T2D for about 8 years. Upon completion of vitamin D(3) supplementation, serum 25 (OH) D levels increased with 50,000 IU (+34 ng/mL) and 5,000 IU (+10 ng/mL). There was no difference in CES-D scores by treatment dose. Overall, depressive symptoms significantly improved over time with an average CES-D decline of 12.98 points (95% CI: −15.04 to −10.93; p < 0.001). Among women with moderate baseline depressive symptoms, those receiving the lower dose had nominally lower depression scores at follow-up than those in the higher dose cohort. Among women with severe baseline depressive symptoms, the improvement in follow-up depression scores was the same regardless of dose. CONCLUSIONS: There was no difference in the dosing effect of vitamin D(3) supplementation for the treatment of depressive symptoms in women with T2D who present with significant symptoms and low vitamin D. Regardless of the dose, participants' mood improved over time. Further study of vitamin D to target depressive symptoms in comorbid populations is needed. Hindawi 2022-03-03 /pmc/articles/PMC8913152/ /pubmed/35280228 http://dx.doi.org/10.1155/2022/4090807 Text en Copyright © 2022 Sue Penckofer et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Penckofer, Sue
Ridosh, Monique
Adams, William
Grzesiak, Meghan
Woo, Jennifer
Byrn, Mary
Kouba, Joanne
Sheean, Patricia
Kordish, Colleen
Durazo-Arvizu, Ramon
Wallis, Diane
Emanuele, Mary Ann
Halaris, Angelos
Vitamin D Supplementation for the Treatment of Depressive Symptoms in Women with Type 2 Diabetes: A Randomized Clinical Trial
title Vitamin D Supplementation for the Treatment of Depressive Symptoms in Women with Type 2 Diabetes: A Randomized Clinical Trial
title_full Vitamin D Supplementation for the Treatment of Depressive Symptoms in Women with Type 2 Diabetes: A Randomized Clinical Trial
title_fullStr Vitamin D Supplementation for the Treatment of Depressive Symptoms in Women with Type 2 Diabetes: A Randomized Clinical Trial
title_full_unstemmed Vitamin D Supplementation for the Treatment of Depressive Symptoms in Women with Type 2 Diabetes: A Randomized Clinical Trial
title_short Vitamin D Supplementation for the Treatment of Depressive Symptoms in Women with Type 2 Diabetes: A Randomized Clinical Trial
title_sort vitamin d supplementation for the treatment of depressive symptoms in women with type 2 diabetes: a randomized clinical trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913152/
https://www.ncbi.nlm.nih.gov/pubmed/35280228
http://dx.doi.org/10.1155/2022/4090807
work_keys_str_mv AT penckofersue vitamindsupplementationforthetreatmentofdepressivesymptomsinwomenwithtype2diabetesarandomizedclinicaltrial
AT ridoshmonique vitamindsupplementationforthetreatmentofdepressivesymptomsinwomenwithtype2diabetesarandomizedclinicaltrial
AT adamswilliam vitamindsupplementationforthetreatmentofdepressivesymptomsinwomenwithtype2diabetesarandomizedclinicaltrial
AT grzesiakmeghan vitamindsupplementationforthetreatmentofdepressivesymptomsinwomenwithtype2diabetesarandomizedclinicaltrial
AT woojennifer vitamindsupplementationforthetreatmentofdepressivesymptomsinwomenwithtype2diabetesarandomizedclinicaltrial
AT byrnmary vitamindsupplementationforthetreatmentofdepressivesymptomsinwomenwithtype2diabetesarandomizedclinicaltrial
AT koubajoanne vitamindsupplementationforthetreatmentofdepressivesymptomsinwomenwithtype2diabetesarandomizedclinicaltrial
AT sheeanpatricia vitamindsupplementationforthetreatmentofdepressivesymptomsinwomenwithtype2diabetesarandomizedclinicaltrial
AT kordishcolleen vitamindsupplementationforthetreatmentofdepressivesymptomsinwomenwithtype2diabetesarandomizedclinicaltrial
AT durazoarvizuramon vitamindsupplementationforthetreatmentofdepressivesymptomsinwomenwithtype2diabetesarandomizedclinicaltrial
AT wallisdiane vitamindsupplementationforthetreatmentofdepressivesymptomsinwomenwithtype2diabetesarandomizedclinicaltrial
AT emanuelemaryann vitamindsupplementationforthetreatmentofdepressivesymptomsinwomenwithtype2diabetesarandomizedclinicaltrial
AT halarisangelos vitamindsupplementationforthetreatmentofdepressivesymptomsinwomenwithtype2diabetesarandomizedclinicaltrial